Summary
- •Scale: ₹939.70 Cr. Mainboard issue.
- •Timeline: Bidding from 10 August 2026 to 12 August 2026.
- •Pricing: ₹768 to ₹807 per share.
Molbio Diagnostics officially launches its Initial Public Offering (IPO) to raise capital from the primary markets. As institutional and retail demand remains robust across the broader equity spectrum, this issue presents a highly anticipated opportunity for portfolio allocation.
Financial Trajectory
Evaluating the statutory financial disclosures, Molbio Diagnostics has demonstrated consistent revenue acceleration, posting a 73.10% shift in recent periods. Bottom-line profitability metrics reveal a 96.48% adjustment in Profit After Tax (PAT), indicating strong operational leverage and margin expansion. Investors must strictly compare these metrics against listed peers before allocating capital.
The definitive basis of allotment is projected for 13 August 2026, paving the way for secondary market listing on 17 August 2026.
Sources & Verification
- Financial Data:Extracted directly from the company's Draft Red Herring Prospectus (DRHP) and official exchange filings (BSE/NSE).
- Market Premium:Aggregated from unregulated grey market dealers. GMP is unofficial, indicative only, and does not guarantee listing performance.
- Review Process:Data and textual analysis independently verified by the IPO Chowk Research Desk.